Merck profit beats, but Keytruda sales fail to impress

Bristol-Myers Squibb (BMY) Reports EMA Approval for Opdivo (nivolumab)

Bristol-Myers Squibb Company (NYSE: BMY) today announced that the European Commission (EC) has approved Opdivo (nivolumab) for the adjuvant treatment of adult patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection. This indication is for both BRAF mutant and wild-type... More

Merck (MRK), Eisai Co. Granted FDA Breakthrough Therapy Designation for LENVIMA

Eisai Co., Ltd. and Merck & Co., Inc. Kenilworth, N.J., U.S.A. (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for LENVIMA (generic name: lenvatinib mesylate), the orally available kinase inhibitor discovered by Eisai, in combination with Merck & Co., Inc., Kenilworth, N.J., U.S.A.'s anti-PD-1 therapy KEYTRUDA (generic name: pembrolizumab) for the potential treatment of patients with advanced and/or metastatic non-microsatellite instability high (MSI-H)/proficient mismatch repair (pMMR) endometrial carcinoma... More

Eli Lilly & Co. (LLY) Extends Cancer Research Collaboration with Dana-Farber Cancer Institute

Eli Lilly and Company (NYSE: LLY) today announced a three-year extension of its cancer research collaboration with Dana-Farber Cancer Institute. Since 2015, scientists from Lilly and Dana-Farber have been working together on pre-clinical and clinical studies, molecular analyses of patient samples and the design and conduct of clinical trials to help advance cancer care.

"We are pleased to announce the extension of our collaboration with Dana-Farber Cancer Institute. This collaboration provides an opportunity for... More

Merck (MRK) Reports Positive Opinion from EMA for KEYTRUDA (pembrolizumab) Combination with Pemetrexed & Platinum Chemotherapy

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of KEYTRUDA®, Mercks anti-PD-1 therapy, in combination with pemetrexed (ALIMTA®) and platinum chemotherapy (cisplatin or carboplatin) for the first-line treatment of metastatic nonsquamous non-small cell lung cancer (NSCLC) in adults whose tumors have no EGFR or ALK genomic tumor aberrations, regardless of PD-L1 expression. If approved, this would mark the first approval in Europe for an... More

Bristol-Myers Squibb Co. (BMY) PT Raised to $57 at BMO Capital

BMO Capital raised its price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $57.00 (from $51.00) while maintaining a Market Perform rating.

Analyst Alex Arfaei commented, "Bristol had a good 2Q but expectations had risen, which, coupled with untimely (CHMP RCC) news, pressured BMY. The... More